EBMT 2022 | CAR-NK clinical trials
In this video, Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, highlights recent updates in clinical trials investigating the use of chimeric antigen receptor-engineered natural killer cells (CAR-NKs) for the treatment of hematological malignancies. Prof. Ullrich first summarizes the promising results observed in CAR-T clinical trials, and the benefits of using NK cells as another treatment approach in heavily pre-treated patients. Following this, Prof. Ullrich discusses some results from a Phase I clinical trial which investigated the use of CD19 CAR-NKs, including the overall response rate in patients and safety profile of these cells. To conclude, Prof. Ullrich explains that while there are not many CAR-NK trials out at the moment, new technologies such as the Sleeping Beauty technology will significantly improve the future development of clinical trials in this field. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
